Kintara Therapeutics Inc (KTRA)

[biotechrulz]

Shorting or Selling DMPI stock right now is VERY UNWISE. Shorts sellers take notice: DMPI stock is NOT A WISE choice to SHORT and here is why:

1) Perfect buyout candidate (I am very confident this company will be bought out) A fundamental of investing is that you never ever short companies with buyout potential.

2) Solid Financials (DMPI fully funded through 2017 as per DMPI May 13th 2016 press release)

3) 3 Orphan Drug Designations (Orphan drug designations are the hottest thing in Biotech right now and makes DMPI a very attractive buyout candidate.

4) Excellent phase II clincial data just received for their brain cancer trials

5) Phase III for brain cancer to be intitated this year

6) uplisting to senior stock exchange next month

7) Warrants may come due this month if DMPI can close above $6.40 for about another 9 days, which would raise about an addition 3 million dollars;

8) A product that treats a variety of different cancers (including Brain cancer (which the most lethal form of cancer), ovarian cancer, cervical cancer, lung cancer, hematological blood cancer; and

9) Approved cancer products in China for lung cancer and leukemia.

So short sellers you would be advised to pick another of the myriad of biotech stocks to shorts and not DMPI because otherwise you could lose your shirt soon. Don't say I didn't warn you